stable lyophilized pharmaceutical formulation of a recombinant von Willebrand factor (rVWF) comprising: (a) a rVWF (B) one or more buffer agents (C) one or more amino acids (D) one or more stabilizing agents and (e) one or more surfactants, preparing said formulation by lyophilization of a solution comprising: (a) said rVWF comprising a polypeptide selected from the group consisting of: a) the amino acid sequence of SEQ ID NO: 3 b) an analogue, fragment or variant of a) capable of causing platelet aggregation in the presence of ristocetin stabilized or bind Factor VIII c) a polypeptide encoded by the nucleotide dee SEQ ID No. 1 d) an analogue, fragment or variant of c) capable of causing platelet aggregation in the presence of ristocetin stabilized or bind Factor VIII e) a polypeptide encoded by a nucleotide that hybridizes to the polynucleotide of SEQ ID NO: 1 under moderately stringent hybridization (B) said buffer comprising a buffering agent in the pH range of about 0.1 mM and about 500 mM and a pH of about 2.0 to about 12.0 (C) said amino acid at a concentration of about 1 to about 500 mM being present (D) said stabilizing agent being present at a concentration of about 0.1 mM to aproximadamente1.000 and (e) said surfactant present at a concentration of about 0.01 g / 0.5 g / l being.Formulación farmacéutica estable liofilizada de un factor von Willebrand recombinante (rVWF) que comprende: (a) un rVWF (b) uno o más agentes tampón (c) uno o más aminoácidos (d) uno o más agentes estabilizantes y (e) uno o más tensioactivos, preparándose dicha formulación mediante la liofilización de una solución que comprende: (a) dicho rVWF, comprendiendo un polipéptido seleccionado de entre el grupo consistente en: a) la secuencia de aminoácidos de SEQ ID Nº 3 b) un análogo, fragmento o variante de a) capaz de causar la aglutinación de las plaquetas estabilizadas en presencia de ristocetina o de unirse al Factor VIII c) un polipéptido codificado por el nucleótido dee SEQ ID Nº
